Dr. Beth Karlan is a leader in the field of research on early detection of ovarian cancer. She has received research grants from the Department of Defense, National Institutes of Health and the American Cancer Institute. Her research interests include the genetic definition and phenotypic determinants of human ovarian carcinomas, molecular biomarker discovery and inherited cancer susceptibility. This year, she is our winner of the Rosalind Franklin Excellence in Ovarian Cancer Research Award due to her commitment to innovative ovarian cancer research.
Related Topics
The Overview: November 2025
Friends, As we approach the end of the year, one thing stands out above all else: this is a moment of unprecedented opportunity to accelerate progress against ovarian and all gynecologic cancers. And thanks to you, OCRA is rising to meet that moment — driving innovation, expanding support, and providing the community that so many … Continued
OCRA Board Member Laura Shawver, PhD, Named to Fierce 50 of 2025
Ovarian Cancer Research Alliance (OCRA) congratulates board member Laura Shawver, PhD, on her selection to the Fierce 50 of 2025, a leading industry award from Fierce Life Sciences recognizing individuals and organizations advancing what’s possible in health, science and patient care. Dr. Shawver was selected for her long-standing leadership in oncology research and drug development, … Continued
Make 2X the Difference with OCRA on GivingTuesday
On GivingTuesday, YOU Can Help Shape the Future of Ovarian and Gynecologic Cancer Care GivingTuesday gifts—including early gifts—will be matched by a generous OCRA board member, dollar for dollar, up to $500,000. That means your $1 = $2 to improve care, foster hope, and bring us closer to a cure. Ovarian Cancer Research Alliance (OCRA) … Continued